Sanofi has entered into an agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop and commercialize the Phase 3 vaccine candidate for extraintestinal pathogenic E.coli (9-valent) developed by Janssen. The agreement combines Janssen’s science behind this potential first-in-class product and Sanofi’s worldwide manufacturing footprint and expertise in launching vaccines.   Both parties will co-fund current and future R&D costs. Janssen will receive $175 mill...